XOMA Royalty (XOMA) Competitors $26.17 -0.79 (-2.93%) As of 07/7/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. INVA, DVAX, MNKD, OPK, NVAX, GERN, RGLS, MYGN, ZBIO, and RIGLShould you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry. XOMA Royalty vs. Its Competitors Innoviva Dynavax Technologies MannKind OPKO Health Novavax Geron Regulus Therapeutics Myriad Genetics Zenas BioPharma Rigel Pharmaceuticals Innoviva (NASDAQ:INVA) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation. Does the media favor INVA or XOMA? In the previous week, XOMA Royalty had 1 more articles in the media than Innoviva. MarketBeat recorded 1 mentions for XOMA Royalty and 0 mentions for Innoviva. XOMA Royalty's average media sentiment score of 0.74 beat Innoviva's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the news media. Company Overall Sentiment Innoviva Neutral XOMA Royalty Positive Which has more risk and volatility, INVA or XOMA? Innoviva has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, XOMA Royalty has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Do analysts recommend INVA or XOMA? Innoviva presently has a consensus target price of $55.00, suggesting a potential upside of 190.85%. XOMA Royalty has a consensus target price of $69.50, suggesting a potential upside of 165.57%. Given Innoviva's higher possible upside, analysts clearly believe Innoviva is more favorable than XOMA Royalty.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innoviva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00XOMA Royalty 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in INVA or XOMA? 99.1% of Innoviva shares are held by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are held by institutional investors. 2.3% of Innoviva shares are held by insiders. Comparatively, 9.1% of XOMA Royalty shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, INVA or XOMA? Innoviva has higher revenue and earnings than XOMA Royalty. XOMA Royalty is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnoviva$358.71M3.31$23.39M-$1.01-18.72XOMA Royalty$13.05M24.00-$13.82M-$1.15-22.76 Is INVA or XOMA more profitable? XOMA Royalty has a net margin of -13.04% compared to Innoviva's net margin of -16.15%. Innoviva's return on equity of 15.77% beat XOMA Royalty's return on equity.Company Net Margins Return on Equity Return on Assets Innoviva-16.15% 15.77% 8.41% XOMA Royalty -13.04%-12.43%-4.85% SummaryInnoviva beats XOMA Royalty on 8 of the 14 factors compared between the two stocks. Get XOMA Royalty News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$322.63M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.07%P/E Ratio-22.7620.4427.2220.04Price / Sales24.00181.20380.3292.37Price / CashN/A41.7026.2128.59Price / Book3.777.397.945.55Net Income-$13.82M-$55.04M$3.17B$248.49M7 Day Performance-0.65%2.51%1.81%4.87%1 Month Performance3.64%-0.21%1.28%6.63%1 Year Performance6.17%3.41%33.57%20.38% XOMA Royalty Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA Royalty4.2938 of 5 stars$26.17-2.9%$69.50+165.6%+2.1%$322.63M$13.05M-22.7610INVAInnoviva3.8567 of 5 stars$20.09+0.7%$55.00+173.8%+15.6%$1.25B$358.71M-19.89100DVAXDynavax Technologies4.3732 of 5 stars$9.92+0.1%$24.00+141.9%-8.4%$1.19B$277.25M-19.08350MNKDMannKind2.5173 of 5 stars$3.74-0.5%$10.33+176.3%-31.0%$1.14B$285.50M37.40400Negative NewsOPKOPKO Health4.2186 of 5 stars$1.32flat$2.75+108.3%+6.3%$1.05B$713.10M-18.852,997NVAXNovavax4.4691 of 5 stars$6.30-1.1%$17.00+169.8%-44.5%$1.03B$682.16M2.381,990GERNGeron2.8548 of 5 stars$1.41-5.4%$5.06+259.0%-69.8%$949.01M$76.99M-6.7170Gap DownRGLSRegulus Therapeutics1.5535 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830MYGNMyriad Genetics4.1209 of 5 stars$5.31+1.1%$14.38+170.9%-78.8%$483.93M$837.60M-4.742,700ZBIOZenas BioPharma1.1945 of 5 stars$9.69+1.1%$36.67+278.4%N/A$400.77M$5M-2.73N/APositive NewsRIGLRigel Pharmaceuticals2.3709 of 5 stars$18.73-3.9%$36.40+94.3%+142.2%$348.15M$179.28M9.05160 Related Companies and Tools Related Companies Innoviva Alternatives Dynavax Technologies Alternatives MannKind Alternatives OPKO Health Alternatives Novavax Alternatives Geron Alternatives Regulus Therapeutics Alternatives Myriad Genetics Alternatives Zenas BioPharma Alternatives Rigel Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.